A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Phase 3
Active, not recruiting
NCT06095115
| Condition | Plaque Psoriasis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Janssen Research & Development, LLC |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 684 participants |
|---|
| Interventions | JNJ-77242113 |
|---|
| Start date | Oct 12, 2023 |
|---|
| Completion date | Jul 29, 2024 |
|---|
| Results posted | Jun 1, 2026 |
|---|
Summary
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of Participants
| Placebo to JNJ-77242113 200 mg | 8.3 Percentage of Participants |
|---|
| JNJ-77242113 200 mg | 64.7 Percentage of Participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 56.4 (95% CI 50.4–61.7) |
|---|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Week 16 · Percentage of participants
| Placebo to JNJ-77242113 200 mg | 4.4 Percentage of participants |
|---|
| JNJ-77242113 200 mg | 49.6 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 45.1 (95% CI 39.5–50.4) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.